| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 17.3% | Wedbush | → $16 | Initiates Coverage On | → Outperform |
| 09/20/2023 | 9.97% | Jefferies | $11 → $15 | Upgrades | Hold → Buy |
| 08/11/2023 | 2.64% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
| 07/27/2023 | -4.69% | Berenberg | → $13 | Initiates Coverage On | → Hold |
| 07/14/2023 | -8.36% | Citigroup | $11 → $12.5 | Maintains | Neutral |
| 04/25/2023 | -4.69% | Barclays | $15 → $13 | Maintains | Equal-Weight |
| 04/20/2023 | -19.35% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/19/2023 | -19.35% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/12/2023 | -4.69% | Credit Suisse | → $13 | Reiterates | → Neutral |
| 03/29/2023 | -4.69% | Truist Securities | $14 → $13 | Maintains | Buy |
| 03/28/2023 | -23.02% | Citigroup | $13 → $10.5 | Maintains | Neutral |
| 12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 11/14/2022 | -4.69% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
| 10/10/2022 | -4.69% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 06/30/2022 | 2.64% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
| 05/25/2022 | 9.97% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
| 04/18/2022 | 2.64% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
| 04/04/2022 | 9.97% | Credit Suisse | $14 → $15 | Maintains | Neutral |
| 03/11/2022 | 9.97% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
| 02/23/2022 | 31.96% | Stifel | $21 → $18 | Maintains | Buy |
| 02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 02/01/2022 | 2.64% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 09/30/2021 | 31.96% | Truist Securities | → $18 | Upgrades | Hold → Buy |
| 09/13/2021 | 46.63% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
| 05/21/2021 | 53.96% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
| 05/10/2021 | 53.96% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
| 01/13/2021 | 46.63% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
| 01/08/2021 | 39.3% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
| 12/03/2020 | 75.95% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
| 09/02/2020 | 9.97% | Stifel | → $15 | Reinstates | → Hold |
| 06/23/2020 | 9.97% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
| 06/22/2020 | 2.64% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
| 05/18/2020 | 9.97% | Berenberg | → $15 | Upgrades | Hold → Buy |
| 04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
| 04/07/2020 | -26.69% | Citigroup | $20 → $10 | Maintains | Neutral |
| 03/26/2020 | -23.02% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
| 02/26/2020 | 61.29% | Mizuho | → $22 | Upgrades | Neutral → Buy |
| 02/06/2020 | 83.28% | Barclays | $26 → $25 | Maintains | Overweight |
| 02/05/2020 | 61.29% | Berenberg | → $22 | Initiates Coverage On | → Hold |
| 12/20/2019 | 61.29% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
| 12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
| 09/27/2019 | 68.62% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 09/23/2019 | 46.63% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
| 09/03/2019 | 75.95% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
| 12/17/2018 | 39.3% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
| 11/16/2018 | 53.96% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
| 11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/13/2018 | 53.96% | Mizuho | → $21 | Downgrades | Buy → Neutral |
What is the target price for Sabra Health Care REIT (SBRA)?
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by Wedbush on October 3, 2023. The analyst firm set a price target for $16.00 expecting SBRA to rise to within 12 months (a possible 17.30% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by Wedbush, and Sabra Health Care REIT initiated their outperform rating.
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a initiated with a price target of $0.00 to $16.00. The current price Sabra Health Care REIT (SBRA) is trading at is $13.64, which is within the analyst's predicted range.